Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CD5KO anti-CD5 CAR 4-1BB-expressing T lymphocytes and autologous CD5KO T lymphocytes

A dual-population preparation of autologous T lymphocytes in which the tumor-associated antigen (TAA) CD5 is knocked out (CD5KO) and is genetically modified to express a chimeric antigen receptor (CAR) specific for CD5 and coupled to the co-stimulatory molecule 4-1BB (CD137), and autologous CD5KO normal untransduced T lymphocytes, with potential immunomodulating and antineoplastic activities. Upon administration of autologous CD5KO anti-CD5 CAR 4-1BB-expressing T lymphocytes and autologous CD5KO T lymphocytes, the autologous CD5KO anti-CD5 CAR 4-1BB-expressing T lymphocytes specifically recognize and kill CD5-expressing tumor cells. CD5 is a T-cell surface glycoprotein expressed on the surface of normal T cells and overexpressed on various B- and T-cell malignancies. CD5 KO in the CART5 cells prevents CART fratricide and enhances CAR-T cell function. The CD5KO normal T cells allow for T-cell reconstitution and may mitigate T-cell toxicity.
Synonym:autologous CD5-deleted anti-CD5 CAR-T cells and CD5-deleted T cells
autologous CD5KO anti-CD5 CAR 4-1BB-expressing T lymphocytes plus autologous CD5KO T lymphocytes
autologous CD5KO CART5 cells and CD5KO normal untransduced T cells
autologous Senza5 (R) CART5 cells
CD5 knockout cells and CD5KO-CART5 cells
Search NCI's Drug Dictionary